8-K
filed May 18, 2023, 7:59 PM ET
ticker VRTX
CIK 0000875320
other
confidence high
sentiment neutral
materiality 0.10
Vertex shareholders elect all nine director nominees at 2023 annual meeting
VERTEX PHARMACEUTICALS INC / MA
- All nine director nominees elected; votes ranged from 203.8M to 223.0M in favor.
- Ernst & Young ratified as independent auditor for 2023: 226.5M for, 7.8M against.
- Advisory approval of 2022 executive compensation passed with 200.9M for (~89% of votes cast).
- Shareholders recommended annual frequency for future advisory votes (222.8M for 1 year); board adopts annual schedule.
- Non-votes on director election, compensation, and frequency proposals were 9.8M shares (broker non-votes).
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
VERTEX PHARMACEUTICALS INC / MA shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for year ending December 31, 2023 at the 2023-05-17 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-17
Exact text from the filing
Proposal No. 2 : Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023: For Against Abstain Non-Votes 226,512,223 7,826,181 151,725 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
VERTEX PHARMACEUTICALS INC / MA shareholders approved Advisory vote on frequency of future advisory votes on executive compensation at the 2023-05-17 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2023-05-17
Exact text from the filing
Proposal No. 4: Based upon the following votes, the shareholders recommended, on an advisory basis, to hold future advisory votes to approve executive compensation on an annual basis: 1 Year 2 Years 3 Years Abstain Non-Votes 222,845,689 100,872 1,607,838 109,401 9,826,329
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of the nine nominees to serve as directors at the 2023-05-17 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-17
Exact text from the filing
Proposal No. 1 : Based upon the following votes, the shareholders elected Sangeeta Bhatia, Lloyd Carney, Alan Garber, Terrence Kearney, Reshma Kewalramani, Jeffrey Leiden, Diana McKenzie, Bruce Sachs and Suketu Upadhyay to serve as members of the Company's Board of Directors until the annual meeting of shareholders to be held in 2024: For Against Abstain Non-Votes Sangeeta Bhatia 222,080,665 2,466,298 116,837 9,826,329 Lloyd Carney 209,020,156 15,522,060 121,584 9,826,329 Alan Garber 222,238,564 2,300,900 124,336 9,826,329 Terrence Kearney 212,386,123 12,155,694 121,983 9,826,329 Reshma Kewalramani 222,944,919 1,605,123 113,758 9,826,329 Jeffrey Leiden 216,063,881 7,824,259 775,660 9,826,329 Diana McKenzie 222,081,247 2,466,571 115,982 9,826,329 Bruce Sachs 203,818,027 20,714,176 131,597 9,826,329 Suketu Upadhyay 222,991,778 1,551,263 120,759 9,826,329
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
VERTEX PHARMACEUTICALS INC / MA shareholders approved Advisory approval of 2022 compensation program for named executive officers at the 2023-05-17 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-05-17
Exact text from the filing
Proposal No. 3 : Based upon the following votes, the shareholders approved, on an advisory basis, the 2022 compensation program for the Company's named executive officers: For Against Abstain Non-Votes 200,867,116 23,641,105 155,579 9,826,329
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.